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Summary New tricyclic derivatives with cyc1ocondensed pyrido-pyrazine 7,10 and pyrido-diazepine 20a,20b 
skeletons were synthetized and biologically investigated. The compounds, preliminarily tested on explorative, 
muscle relaxing, antinociceptive, spontaneous motor activities and influence on the narcotic effect of Evipan. 
revealed interesting eNS depressant and analgesic activities. The pyrido[2,3-e)pyrrolo[1 ,2-a)pyrazine structure 
of 7 appeared the most promising for analgesic and neuroleptic activities. The above compounds were assayed 
also for their capacity to inhibit DNA synthesis in Ehrlich ascites tumor cells; lOa appeared to be able of inducing 
a significant inhibition. 
In the field of our research on heteropolycyclic 
tructures2.3 that may show biological activities, we 
lescribed in preceding papers pyrido-pyrazine4 and 
pyrido-diazepine derivatives5 with neuroleptic activity. 
As an extension of this study and with the aim of 
determining the influence resulting from the structural 
differences on pharmaceutical response, we have now 
prepared heterotricyclic systems, corresponding to 
general formula A, in which the above structures are 
fused with pyrrolidine or piperidine rings. These 
compounds were tested for the above pharmacological 
activity. Moreover, since various policyclic compounds 
can interact with DNA and/ or can inhibit the activity 
of some important enzymes involved in DNA 
replication, we studied also their ability to inhibit DNA 
synthesis in the Ehrlich cells, a well-known tumor cell 









(*) Part HI of the series "Heterotricyc1ic systems" 
(**) To whom correspondence should be addressed. 
The synthetic approach to the required 7,8-dihydro-
5-methylpyrido [2,3 -e] pyrrole [1, 2-a] pyrazin-
6,9(5H,6aH)-dione 7 and 6a,7 ,8,9-tetrahydro-5-methyl-
5H-dipyrido[I ,2-a:2,3-e]pyrazin-6, IO-dione 14 
consisted in the condensation in boiling ethanol of 3-
amino-2-methylaminopyridine 1 with 2-ketoglutaric 
acid 3 and diethyl 2-oxoadipate 4 respectively, as 
depicted in Scheme 1. The carboxy derivatives 5 and 
12 were reduced with sodium borohydride in diluted 
sodium hydroxide solution; occasionally, during the 
course of the reduction, a partial cyclization from 6 
to 7 occurred, which was completed by heating in 
vacuo, whereas the cyclization of 13 to 14 was carried 
out by fusion in vacuo of the isolated intermediate. The 
synthesis of 10 was accomplished similarly starting from 
2-amino-3-methylaminopyridine 2 and 3 and was 
realized in order to study the structure-activity 
correlations with the isomer 7. 
. The reaction to obtain the cycloomologues 20 
(Scheme 2) was carried out using the above described 
procedure under different conditions. Starting from 1 
and diethyl 2-oxoadipate 15a in hot xylene the expected 
17a was obtained, while 1 and diethyl 2-oxopimelate 
15b afforded 17b, in addition to a small amount of 
imidazo[2,3-b]pyridine derivative 16 whose formation 
can be explained by the cyclization of intermediate 
16*6.7. Compounds 17a,b were hydrogenated with 
Raney nickel under pressure to 18a,b, whose alkaline 
hydrolysis gave 19a,b without concomitant cyclization. 
The fusion in vacuo of 19a,b afforded smoothly 
7,7 a, 8, 9-tetrahydro-5 -methy 1-5H-pyrido[2, 3-
b]pyrrole[l,2-d] diazepin-6,1O-dione 20a and 7a,8,9,1O-
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tetrahydro-7 -methyl-5H-dipyrido[l ,2-d:2,3-bJdiazepin-
6,1 1 (5H,7H)-dione 20b, respectively. 
The structures of all described compounds were 
supported by analytical and spectroscopic data. In 
particular reduced 9 and 13 showed a complex triplet 
(0 4.0) and an exchangeable signal (0 6.5-7.0) 
attributable to the methineproton and to NH, 
respectively. Similarly, the homologous compounds 
18a,b and 19a,b exhibited the methine signal at 0 4.0, 
while the exchangeable peak of NH shifts to 0 3.6-5.5. 
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investigated for eNS activities and tested for their 




Melting points were determined by the capillary method on a 
Btichi 510 apparatus and are uncorrected. UV spectra were measured 
in 95 070 ethanol with a Perkin-Elmer Model 550S spectrophotometer. 
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Pyridopyrazinones and diazepinones derivatives 261 
IR spectra were recorded on a Perkin-Elmer Model 297 
spectrophotometer and IH-NMR spectra were recorded on a 
Varian-Gemini 200 spectrometer with TMS as internal standard. 
Elemental analyses for C, H, N were performed on the Carlo Erba 
Elemental Analyser Model 1106 at the Microanalytical Laboratory, 
Istituto di Scienze Farmaceutiche, Universita di Genova, and were 
within :I:: 0.4070 of the theoretical values. 
REACTIONS BETWEEN AMINOPYRIDINES AND a-KETOACIDS 
a) 2-(2-Carboxyethyl)-4-methyl-pyrido[2,3-bJpyrazin-3(4H)-one 
5 - To a suspension of 2-ketoglutaric acid 3 (2.95 g, 20 mmoles) 
in ethanol (15 ml) was added an ethanol solution (20 ml) of 3-arnino-
2-methylaminopyridine 1 (2.5 g, 20 mmoles), obtained by 
hydrogenation at atmospheric pressure of 2-methylamino-3-
nitropyridine, and the mixture was refluxed with stirring for 90 min. 
The solution was evaporated under reduced pressure to give S as 
a solid which was collected by filtration and recrystallized from 
ethanol. mp 194-196 °C (yield 88%). UV: ~max nm (log e): 220 
(4.41),322 sh (4.06), 331 (4.07); IR (KBr): 3190,1740,1635 cm-I; 
'H-NMR (CDCI): 0 2.93 (t, 1 = 6.8 Hz, 2H), 3.30 (t, 1 = 6.8 Hz, 
2H), 3.82 (s, 3H), 7.30 (dd, 1=7.9 Hz, pyr (3-H), 8.09 (dd, 1=7.9 
Hz, pyr oy-H), 8.56 (dd, 1 =4.6 Hz, pyr a-H), 10.10 (br s, OH, 
exchangeable). 
Anal. (CIIHIIN)O) C,H,N. 
b) 3 -(2-Carboxyethyl)-4-methyl-p yrido[2, 3-bJp yrazin-2( 1 H)-one 
B - In a similar manner, starting from 2-amino-3-
methylaminopyridine 2 and 3, 8 was obtained in 60% yield, mp 
210-213 QC (ethanol). UV: ~m .. nm (log e): 222 (4.28), 328 sh 
(3.92), 331 (3.95); IR (KBr): 3400, 1710, 1660 cm-I; 'H-NMR 
(DMSO-d6): 02.78 (t, 1=6.4 Hz, 2H), 3.14 (t, 1=6.4 Hz, 2H), 
3.62 (s, 3H), 7.62 (dd, 1=7.6 Hz, pyr (3-H), 8.15 (dd, 1=7.2 Hz, 
pyr oy-H) , 8.58 (dd, 1 = 4.3 Hz, pyr a-H), 12.18 (s, OH, 
exchangeable). 
Anal. (CIIHIIN)O) C,H,N. 
c) 2-(2-Ethylcarboxypropyl)-4-methyl-pyrido[2,3-bJpyrazin-3(4H)-
one 11 - Starting from 1 and diethyl 2-oxo-adipate 48 and 
following the same procedure described above, 11 was obtained in 
85% yield, mp 117-119 QC (ethanol). IR (CHCI): 1725, 1660 
cm -I; 'H-NMR (CDCh): 0 1.26 (t, 1 = 7.2 Hz, 3H), 2.17 (m, 2H), 
2.48 (t, J = 7.7 Hz, 2H), 3.02 (t, 1 = 7.2 Hz, 2H), 3.80 (s, 3H), 4.14 
(q, 1=7.1 Hz, 2H), 7.31 (dd, 1=8.0Hz, pyr(3-H), 8.13 (dd, 1=8.0 
Hz, pyr oy-H), 8.55 (dd, 1 = 2.5 Hz, pyr a-H). 
Anal. (C I4H 17N)O) C,H,N. 
7,8-DIHYDRO-5 -METHYL-PYRIDO [2, 3-e )PYRROLE [1 ,2-a )PYRAZIN -6, 9 
(5H,6aH)-DIONE 7 
Sodium borohydride (1.0 g) was added to a solution of S (2 g, 
9 mmoles) in 2N NaOH (10 ml) and the mixture was allowed to 
stand at room temperature for 24 h. The mixture was acidified with 
10% solution of tartaric acid, extracted several times with 
dichloromethane, the combined extracts were washed with water, 
dried (Na2SO.) and evaporated to give an oily residue which was 
let to stand in vacuo at 150°C for I h. After cooling, the residue 
was triturated with ethanol and filtered off to give a solid which 
was suspended in a 5% solution of NaHCO) with stirring for 15 
minutes. Compound 7 was obtained in 46% yield, mp 141-144 QC 
(ethanol). UV: ~max nm (log e): 224 (4.42),293 (4.11); IR (CHCh): 
1705, 1690 cm-I; 'H-NMR (CDCh): 02.62 (m, 4H), 2.54 (s, 3H), 
4.41 (t, J=7.0Hz, IH), 7.08 (dd, 1=8.0 Hz, pyr (3-H), 8.19 (dd, 
1 =4.2 Hz, pyr oy-H), 8.41 (dd, 1 =7.3 Hz, pyr a-H). 
Anal. (C II H II N)02) C,H,N. 
6a,7 ,8,9-TETRAHYDRO-5-METHYL-5H-DIPYRIDO[1 ,2-a:2,3-e)pyRAZIN-
6,IO-DIONE 14 
Compound 11 (2 g, 7 mmoles) was suspended in 2N NaOH (10 
ml) and stirred for 6 h at room temperature. The mixture was washed 
with diethyl ether, neutralized with 10% solution of tartaric acid 
and extracted with dichloromethane to give in 80% yield 2-(3-
carboxypropyl)-4-methyl-pyrido[2,3-b)pyrazin-3(4H)-one 12, mp 
201-203 °C (ethanol). IR (CHCI): 1710, 1660 cm - I; 'H-NMR 
(DMSO-d6): 01.97 (q, 1 = 7.1 Hz, 2H), 2.40 (t, 1 = 7.3 Hz, 2H), 
2.88 (t, 1 = 7.3 Hz, 2H), 3.67 (s, 3H), 7.42 (dd, 1 = 7.6 Hz, pyr (3-
H), 8.22 (dd, 1 = 7.9 Hz, pyr oy-H), 8.61 (dd, 1 = 4.7 Hz, pyr a-H), 
12.07 (OH, exchangeable). 
Anal. (CI2H uN)O) C,H,N. 
Compound 12 was reduced to 13 with sodium borohydride, as 
reported for 7. The reaction mixture was neutralized (10% tartaric 
acid solution), saturated with NaCI and extracted several times with 
dichloromethane. The organic solution was dried (Na2S04) and 
evaporated to give 2-(3-carboxypropyl)-I,2-dihydro-4-methyl-
pyrido[2,3-b)pyrazin-3(4H)-one 13 in yields not higher than 38%, 
mp 118-121 °C (ethanol). IR (Kbr): 3350, 1690, 1630 cm -I; 'H_ 
NMR (DMSO-dJ: 01.62 (m, 4H), 2.24 (m, 2H), 3.38 (s, 3H), 3.92 
(m, IH), 6.40 (br s, NH exchangeable), 6.88 (dd, 1 =7.8 Hz, pyr 
(3-H), 7.08 (dd, 1 = 8.0 Hz, pyr oy-H), 7.70 (dd, 1 = 2.4 Hz, pyr a-
H), ) 2.02 (br s, OH, exchangeable). 
Anal. (CI2H ISN)O) C,H,N. 
Compound 13 was cyclized to 14 in 65% yield by fusion under 
the condition described for 10, mp 110-112 °C (ethanol). UV: ~max 
nm (log e): 287 (3.97); IR (CHCl): 1685 cm -I; IH-NMR (CDCI): 
01.92 (m, 2H), 2.22 (m, lH), 2.58 (m, 3H), 3.51 (s, 3H), 4.08 (t, 
1 = 6.2 Hz, IH), 7.08 (dd, 1 = 8.8 Hz, pyr (3-H), 7.38 (dd, 1 = 9.0 
Hz, pyr oy-H), 8.30 (dd, 1 = 4.8 Hz, pyr a-H). 
Anal. (C I2H IlN)02) C,H,N. 
• 
7 ,8-DIHYDRO-5-METHYL-PYRIDO[3 ,2-e)PYRRoLE[ 1 ,2-a)pYRAZIN-6,9 
(5H,6aH)-DIoNE 10 
Starting from 8, 3-(2-carboxyethyl)-3,4-dihydro-l-methyl-
pyrido[2,3-b)pyrazin-2(IH)-one 9 was obtained in 52% yield by 
reduction with sodium borohydride, mp 163-164 °C (ethanol). ~max 
nm (log e): 213 (4.61), 265 (3.48); 316 (4.03); IR (KBr): 3250,1720, 
1690 cm -I; 'H-NMR (DMSO-d6): 01.88 (m, 2H), 2.34 (m, 2H), 
3.36 (s, 3H), 4.05 (t, 1 = 6.0 Hz, IH), 6.72 (dd, 1 = 8.0 Hz, pyr (3-
H), 7.04 (s, NH, exchangeable), 7.24 (dd, 1 = 8.0 Hz, pyr oy-H), 7.41 
(dd, 1 = 4.0 Hz, pyr a-H), 12.12 (br s, OH, exchangeable). 
. Anal. (CIIHIlN)O) C,H,N. 
Compound 9 gave, by heating in vacuo at melting point for 1 
h, a solid residue which was dissolved in dichloromethane and 
extracted with a 5% NaHCO) solution. The organic solution was 
washed with water, dried (Na~O.) and evaporated to give 10 in 
58% yield as needles, mp 175-177 QC (ethanol). UV: ~m.x nm (log 
e): 224 (4.20), 269 (3.88), 294 (3.88); IR (CHCh): 1725, 1690 cm-I; 
'H-NMR (DMSO-~): 02.28-2.70 (m, 4H), 3.38 (s, 3H), 4.62 (t, 
1 = 12 Hz, IH), 7.31 (dd, 1 = 8.0 Hz, pyr (3-H), 7.67 (dd, J = 8.9 
Hz, pyr oy-H), 8.30 (dd, 1 = 4.6 Hz, pyr a-H). 
Anal. (CIIHlIN)02H20) C,H,N. 
REACTION OF 3-AMJNo-2-ME OPYRIDINE WITH (3-KETOESTERS 
A solution of 1 (2.5 g, 20 mmoles) and diethyl2-oxopimelate 1Sb 
(5.0 g, 22 mmoles) in xylene (100 ml) was refluxed for 20 h. After 
cooling, the solution was extracted with 2N HCI, the acid solution 
was made alkaline with 2N NaOH and extracted with 
dichloromethane. The oily residue obtained after evaporation of 
the combined extracts was dissolved in diethyl ether (10 ml) and 
let to stand in a freezer for a day, whereby a small amount (0.1 
g) of 2-(3-ethylcarboxypropyl)-3-methyl-imidazo[2,3-b)pyridine 16 
was obtained, mp 70-71 °C (diethyl ether). UV: ~ax nm (log e): 
251 (3.65),286 (4.08); IR (CHCh): 1725 cm- I; 'H-NMR (CDCl): 
01.26 (t, 1 = 8.5 Hz, 3H), 2.23 (m, 2H), 2.52 (t, 1 =7.0 Hz, 2H), 
2.98 (t, 1 = 7.0 Hz, 2H), 3.84 (s, 3H), 4.14 (q, 1 = 8.5 Hz, 2H), 7.18 
(dd, 1 = 8.8 Hz, pyr (3-H), 7.97 (dd, 1 = 9.0 Hz, pyr oy-H), 8.32 (dd, 
1 = 4.2 Hz, pyr a-H). 
Anal. (CIlH 17N)02) C,H,N. 
The liquid residue obtained by evaporation of diethyl ether was 
chromatographed on basic alumina. By elution with 
dichloromethane, 3,5-dihydro-2-(ethylcarboxypropyl)-5-methyl-4H-
pyrido[2,3-b)[I,4)diazepin-4-one 17b was collected as an oil (52% 
yield). UV: ~max nm (log e): 294 (3.93); IR (CHCh): 1725, 1670 
cm -I; 'H-NMR (CDCh): 01. 76 (t, 1 = 7.2 Hz, 3H), 2.08 (q, 1 = 6.5 
Hz, 2H), 2.42 (t, 1=2.5 Hz, 2H), 2.68 (t, 1=6.5 Hz, 2H), 3.18 
(m, 2H), 3.49 (s, 3H), 4.13 (q, 1 = 7.2 Hz, 2H), 7.19 (dd, 1 = 6.8 
Hz, pyr (3-H), 7.66 (dd, J =6.8 Hz, pyr oy-H), 8.37 (dd, 1 =4.4 Hz, 
pyr a-H). 
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Anal. (CI5H I9N)O) C,H,N. 
A further elution gave unreacted 1 (8OJo yield). 
The reaction of 1 with diethyl 3-oxo-adipate 15a9 , carried out as 
described above, afforded, 3,5-dihydro-2-(ethylcarboxyethyl)-5-
methyl-4H-pyrido[2,3-b][I,4]diazepin-4-one 17a, as a sole product, 
which in a small amount was separated from the diethyl ether 
solution of combined extracts. A further amount (55 OJo overall yield) 
was collected by chromatography on basic alumina of the oily 
residue obtained by evaporation of diethyl ether. White crystals, 
mp 60-62 °C (diethyl ether); UV: Am .. nm (log E): 295 (3.90); IR 
(CH Cl): 1725, 1670 cm - I; 'H-NMR (CDCh): 01.24 (t, J = 7.0 Hz, 
3H), 2.74 (t, J = 6.2 Hz, 2H), 2.96 (t, J = 6.2 Hz, 2H), 3.18 (m, 2H), 
3.48 (s, 3H), 4.26 (q, J = 7.0 Hz, 2H), 7.18 (dd, J = 5.8 Hz, pyr (3-
H), 7.61 (dd , J = 6.2 Hz, pyr ')'-H) , 8.37 (dd, J = 4.4 Hz, pyr a-H). 
Anal. (C 4H 17N)O) C,H,N. 
REDUCTION OF 17a,b TO 18a,b 
An ethanol suspension of 17a (2.75 g, 10 mmoles) and Raney 
nickel (3 g) was shaken at room temperature in a Parr apparatus 
under 60 psi of hydrogen. After 12 h the uptake of hydrogen ceased, 
the catalyst was filtered off and washed with ethanol. The filtrate 
was concentrated to dryness under reduced pressure affording a 
crude gemisolid product which was triturated with diethyl ether, 
filtered and the solid residue was purified either by chromatography 
on neutral alumina or by crystallization from ethanol. 
1,2,3,5-tetrahydro-2(2-ethylcarboxyethyl)-5-methyl-4H-
pyrido[2,3-b)[I,4]diazepin-4-one 18a was obtained, in 65OJo yield, 
as an oil. UV: Am.x nm (log E): 258 (3.69), 308 (3.74); IR (CHCh): 
1725,1660 cm- I; 'H-NMR (CDCI): 01.25 (t, 1=7.0 Hz, 3H), 1.91 
(m, 2H), 2.30-2.70 (m, 4H), 3.41 (s, 3H), 3.68 (s, NH, 
exchangeable), 3.95 (m, IH), 4.14 (q, ]=7.0 Hz, 2H), 6.98 (dd, 
] = 8.0 Hz, pyr (3-H), 7.16 (dd, J = 8.6 Hz, pyr y-H), 8.11 (dd, J = 4.2 
Hz, pyr a-H). 
Anal. (C I4H I9N)O) C,H,N. 
From 17b, by an identical procedure, 1,2,3,5-tetrahydro-2(3-
ethylcarboxypropyl)-5-methyl-4H-pyrido[2, 3-b] [I ,4]diazepin-4-one 
18b, was obtained in 55OJo yield as a microcrystalline powder; mp 
108-109 cC. VV: Am .. nm (log E): 261 (3.88), 307 (3.77); IR 
(CHCh): 1725, 1660 cm -I; 'H-NMR (CDCh): 01.26 (t, J = 7.0 Hz, 
3H), 1.69 (m, 4H», 2.38 (m, 3H), 2.61 (dd, 1 = 13.0 Hz, lH), 3.49 
(s, 3H), 3.60 (br s, NH, echangeable), 3.89 (m, IH), 4.16 (q,] =7.0 
Hz, 2H), 6.89 (dd, J = 6.4 Hz, pyr (3-H), 7.19 (dd, J = 6.4 Hz, pyr 
')'-H) , 8.11 (dd, ] = 4.2 Hz, pyr a-H). 
Anal. (C I5H 2I N)O) C,H,N. 
It was often difficult to purify the reduced products 18a and 18b 
from unreacted 17a and 17b. In this case we submitted the 
unresolved mixture to the next reaction, because the unreacted 17a,b 
cannot cyclize to 20a,b. 
7, 7a,8,9-TETRAHYDRO-5-METHYL-5H-pYRIDO[2,3-b]pYRROLE[1 ,2-
d)[l ,4]DIAZEPIN-6,IO-DIONE 20a AND 7a,8,9,IO-TETRAHYDRO-5-
METHYLDIPYRIDo[2,3-b: I ,2-d][1 ,4]DIAZEPIN-6,11(5H,7H)-DIONE 20b. 
Compound 18a (2.5 g, 10 mmoles) was suspended in 2N NaOH 
(10 ml). After stirring at room temperature for 6 h, the alkaline 
solution was washed with dichloromethane, neutralized with IOOJo 
solution of tartaric acid and extracted with dichloromethane. The 
solution was dried (Na2S04) and evaporated to dryness to give 
1,2,3, 5-tetrahydro-2-(2-carboxyethyl)-5-methyl-4H -pyrido[2,3-
b][I,4]diazepin-4-one 19a as an oil which was triturated with diethyl 
ether and recrystaIlized from ethanol, mp 143-145 cC. IR (KBr): 
3310,1710,1625 cm-I; 'H-NMR (DMSO-d6): 01.70 (m, 2H), 2.30 
(m, 3H), 3.23 (s, 3H), 3.38 (m, lH), 3.78 (m, IH), 5.46 (br s, NH, 
exchangeable), 7.08 (dd, J = 7.9 Hz, pyr (3-H), 7.38 (dd, J = 7.1 Hz, 
pyr ')'-H), 7.79 (dd, J = 4.5 Hz, pyr a-H), 12.12 (br s, OH, 
exchangeable). 
Anal. (C12H I5N)O) C,H,N. 
Compound 19a was kept up at melting temperature under reduced 
pressure (10 - 1 mm Hg) for one hour. After cooling the residue was 
suspended in dichloromethane and washed with 5OJo solution of 
NaHCO) solution. The organic solution was dried (Na2S04) and 
evaporated to dryness to give an oily residue which was 
chromatographed on neutral alumina eluting with dichloromethane, 
whereby 20a was collected (69OJo yield), mp 139-141 °C (ethanol-
diethyl ether). VV: Am.x nm (log E): 283 (3.85); IR (CHCI): 1700, 
1670 cm - I; 'H-NMR (CDCI): 02.25 (m, 2H), 2.60 (m, 3H), 2.93 
(dd, J = 16.0 Hz, IH), 3.41 (s, 3H), 4.38 (m, lH), 7.23 (dd, J = 10.0 
Hz, pyr (3-H), 7.72 (dd, J = 9.5 Hz, pyr y-H), 8.46 (dd, J = 5.0 Hz, 
pyr a-H). 
Anal. (C12H I)N30 2) C,H,N. 
Starting from 18b and following the above procedure, 1,2,3,5-
te tr ahydro-2-( 3 -car boxypropy 1)-5 -meth y 1-4H -pyrido [2,3-
b][I,4]diazepin-4-one 19b in 76OJo yield, mp 157-159 °C (ethanol). 
IR (KBr): 3310,1715,1630 cm-I; 'H-NMR (DMSO-d6): 01.56 (m, 
4H), 2.28 (m, 3H), 3.38 (m, 3H + IH), 3.78 (m, IH), 5.42 (br s, 
NH, exchangeable), 7.08 (dd, J = 6.0 Hz, pyr (3-H), 7.39 (dd, J = 6.0 
Hz, pyr y-H), 7.98 (dd, J =4.2 Hz, pyr a-H), 12.02 (br s, OH, 
exchangeable). 
Anal. (CnH 17N)O) C,H,N. 
Compound 19b was converted to 20b (76OJo yield) by fusion in 
vacuo, mp 138-139 cC; UV: Am •• nm (log E): 288 (3.86); IR 
(CHCh): 1660 cm-I; 'H-NMR (CDCI): 02.03 (m, 4H), 2.50 (m, 
3H), 2.81 (dd, J = 14.0 Hz, lH), 3.42 (s, 3H), 4.14 (m, lH), 7.22 
(dd, 1 = 9.8 Hz, pyr (3-H), 7.69 (dd, J = 9.0 Hz, pyr ')'-H), 8.42 (dd, . 
] = 4.3 Hz, pyr a-H). 
Anal. (C nH I5N)02) C,H,N. 
B) PHARMACOLOGY 
The following investigation have been worked out on the 
heterotricyclic compounds 7,14,20a and 20b: explorative, muscle 
relaxing, spontaneous motor, antinociceptive activities and influence 
on the narcotic effect of Evipan. 
MATERIAL AND METHODS 
For all the above tests, male Swiss albino mice were used. The 
animals, weighing 18-22 g, were housed at constant temperature 
(20-22 0C). The test compounds were administered s.c. at the dose 
of 115 mmole dissolved in 10 mllkg of PEG 200, 30 min before tests. 
EXPLORATIVE ACTIVITY 
It was detected with the Boissier and Simon test'° using a square 
board 37 cm wide with 16 equidistant holes (2.2 cm diameter), on 
which each animal was kept for 5 min and the explored holes were 
counted. Control animals received only PEG 200. Diazepam (5 
mg/ kg s.c.) was used as a reference drug (Table I, Fig. I). 
T ABLE I . EXPLORATIVE ACTIVITY 
Compound Dose Number of ±S.E. Var. 
(mg/kgl explored holes % 
Controls 24.4 4.66 
Diazepam 5 4.8" 0.86 -80 
7 43 4 .6" 1.6 -81 
14 46 7.6» 1.91 -69 
20 a 46 11.4> 1.32 -53 
20b 49 • 10. 6> 1.21 -57 
Values are expressed as mean ± S.E. of animals. For statistical 
analysis "t" test was used. *p<0.05; ** p<O.OI; n. 5 for each 
substance. 
MOTOR COORDINATION (MUSCLE RELAXING ACTIVITY) 
This activity was evaluated with the Kinnard and Carr" method, 
using a "Rotarod" apparatus (V. Basile, Milano) turning at 16 rpm. 
Six hours before dosing, animals were selected; only those remaining 
on the turning rod for more than 120 sec were utilized. To these 
animals (5 for each compound) the test substances were given 30 
min before the test. Mice that remained on the turning rod for less 
than 2 minutes were considered incoordinate. Diazepam (5 mg/ kg 
s.c.) was used as a reference drug (Table 2, Fig. 2). 
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% variation of explored holes compared to the control 
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Fig. 2 - Muscle relaxing activity. 
• 
TABLE 2· MUSCLE RELAXING ACTIVITY 
Compoud Dose Number of animals 
mg/kg Incoordinate Treated 
Controls 0 5 
Diazepam 5 5 5 
7 43" 4 5 
14 46" 4 5 
20 a 46" 3 5 
20b 49" . 5 5 
* 1/5 mmole/kg/lO ml PEG 200. 
SPONTANEOUS MOTOR ACTIVITY 
Cages similar to those used by Raphaelson and Rabinl2 were 
utilized and the number of movements of the animals were recorded. 
The number of spontaneous movements were registered 30 min after 
the s.c. administration of the compounds and every 30 min for 3 
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Number of spontaneous movements registered 30 minutes after 
the s.c. administration of the CODlllounds and every 30 minutes for 
three hours 
Fig. 3 - Spontaneous motor activity . 








The method of Woolfe - McDonald l3 was used, employing 10 
animals for each compound. The animals were placed on a stainless 
steel plate at 55 ± 0.5 QC and the mean reaction time was determined 
for each group of mice just before the administration of the test 
compounds and 30, 60, 120 and 180 min after the dosing. The 
percent reaction time variations were referred to initial values. The 
animals with an initial reaction time superior to 10 sec were 
discarded. Morphine was used as reference drug at the dose of 10 
mg/kg s.c. (Table 4, Fig. 4). 
INFLUENCE ON THE NARCOTIC EFFECT OF EVIPAN 
The influence on the narcotic effect of Evipan was evaluated by 
strengthening of sleep. Thirty minutes before the intraperitoneal 
injection of Evipan (100 mg/kg), the compounds were administered 
s.c. at the dose of 1/5 mmole/kg dissolved in 10 mllkg of PEG 
200. The sleeping time exobarbital induced was measured against 
that of a series of control animals14• The average length of sleeping 
time was measured, and the percentage of increased sleep in respect 
to the control animals. The control animals received only Evipan 


















% change relative to 0 value 
Fig. 4 - Analgesic activity - Hot plate test. 
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TABLE 3 - SPONTANEOUS MOTOR ACTIVITY. 
Number of spontaneous movements every 30 minutes for three hours after the administration 
Dose 
Compound 30' 60' 90' 120' 150' 180' Average % Change 
(m /k ) 
Controls 1146 793 284 79 108 621 505 
Diazepam 5 509 363 583 322 58 125 327 -35 
7 43" 524 136 139 247 57 93 199 -61 
• 
14 46· 1017 731 404 361 90 259 477 -5 
20a 46" 460 444 69 202 93 437 284 -44 
20b 49" 1163 741 515 459 147 512 589 17 
. 
" : 0.2 nunoles/Kg / 10 mI 
TABLE 4 - ANTINOCICEPTIVE ACTIVITY - HOT PLATE TEST. 
Mean reaction time in seconds (± S.E.) after the dosing 
• 
(% Change relative to 0 value) 
. 
Compound 0 30' % 60' % 120' % 180' % 
Morphine 10 7.03±0.65 11.63±1.75 65 13.52±1.18 92 17.2D±1.79"" 145 13.45±1.85 91 
7 43 6.42±0.86 10.18±1.95 59 8.98±1.08 40 11.35± 1.23"· 108 8.55±1.48 33 
. 
14 46 7.37±0.73 9.68±1.70 31 11.8D±1.89 60 13.15±1.82" 78 1O.33±1.51 40 
20a 46 7.97±0.67 7.25±0.56 -9 11.72±1.75 47 13.5D±2.17" 69 18.88±0.79 36 
20b 49 8.4D±0.56 10.88±1.18 29 14.2D±1.96 69 13.72±2.14" 63 10.08±1.33 20 
SiaiisiiCar analysis v:.as performed using "t"test for paired data, at second hour 







Diazepam 7 14 20 a 20 b 
Percentage of increased sleep in respect.to tbe control animals 
Fig. 5 - Influence on the narcotic effect of evipan (Sleep 
strengthening). 
STATISTICAL ANALYSIS 
The data are expressed as mean values ± standard error of five 
or six animals and percent variation. 
The statistical analyses were performed by using "t" test for 
unpaired data or "t" test II for paired data (hot-plate) at a 
significance level 5070 or 1 %. 
TABLE 5 - INFLUENCE ON THE NARCOTIC EFFECT OF EVIPAN. 
Dose 
Compound Increase % 
(mg/kg) 
Diazepam 2.5 205'" 
7 43 145'" 
14 46 72 u 
20a 46 38" 
20b 49 39" 
For statistical analysis "t" test was used for unpaired data. *: 
p<0.05; **: <0.01; n. 5 for each substance. 
C) BIOLOGICAL ACTIVITY 
EHRLlCH CELLSi5 
Ehrlich ascites tumor (Lettre strain from Heidelberg) was routinely 
transferred by injecting intra peritoneally 2 x 106 cells per animal 
into NCL mice. For the experiments, the tumor cells, collected on 
·the 6(h_7(h day after the transplant, were suspended (2 x 107 ml - ') 
in Hank's solution containing the compound to be tested and were 
incubated at 37°C for 30 min; then, 40 KBq ml - ' of 3H-thymidine 
Pyridopyrazinones and diazepinones derivatives 265 
(4.77 TBq mM -\; from Amersham International L Td, UK) in a 
small volume of the same medium were added and the cells were 
further incubated for 30 min at 37 QC. The acid-insoluble fraction 
was precipitated by adding 5 0J0 ice-cold trichloroacetic acid and 
filtered on Whatman GF/ C filters (2.5 cm in diameter). After several 
washing with cold 1 flJo trichloroacetic acid the filters were dried and 
counted by a Packard A 300 CD liquid scintillation spectrometer. 
The filtrations were carried out with a Sample Manifold apparatus 
(Millipore Corporation, Bedford, USA). 
The results were calculated as percentage of radioactivity 
incorporated into DNA of untreated control cells (about 3-6 MBq); 
the IDso, that is the drug concentration, expressed in /-Ig/ ml, which 
induces a 50fIJo inhibition of DNA synthesis, was then calculated 
by pro bit analysis. 




7 93.66 1.77 
14 Not detectable 
20a 20.91 1.6 
20b Not detectable 
1050 ± Standard deviation expressed /-Ig / kg. 
RESULTS AND DISCUSSION 
The results of the pharmacological screening on 
pyridopyrazinones 7,14 and pyridodiazepinones 20, 20b 
are illustrated in Tables 1-5 and Figures 1-5. 
It is worthy to note that all compounds have marked 
depressant effect on CNS and good analgesic activity 
(central analgesia) at 115 mmollkg. Compound 7 
markedly reduced the spontaneous motor activity, less 
active 20a and diazepam, instead 20b increases it. 
All compounds exhibited a appreciable depression 
of the explorative activity and that of 7 was the same 
as diazepam. 
Concerning the motor coordination, 20b produced 
an incoordination comparable to diazepam while 7 and 
14 were less active. 
Compound 7 markedly potentiated the narcotic effect 
of evipan (Exobarbital). 
Results of the hot plate test, kind of analgesia, 
typically overspinal showed a good central analgesic 
activities particularly produced for 7 and 14. 7 enhanced 
reaction time ( + 1080/0 at 120') being the most potent 
one at the second hour after the administration, 
compared with that of morphine. Other tested 
compounds also showed a stronger activity at the 
second hour. 
Compounds 14 and 20b, tested for their capacity to 
inhibit DNA synthesis in Ehrlich ascites tumor cells, 
did not induce a significant inhibition while the 
compound 7 and still more 20a appeared to be able of 
inducing a significant inhibition (Table 6). 
In conclusion, from these preliminary 
pharmacological assays, it appears that the tested 
compounds revealed interesting CNS depressant and 
analgesic activities particularly appreciable on the 
pyridopirazinone cyclohomologues 7 and 14 and 
support our interest on these tricyclic structures whose 
potentialities will be further investigated. 
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